New small molecules for the treatment of Parkinson's disease

Bibliography

• de Rijk MC, Launer LJ, Berger K, Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(11 Suppl 5):S21-3
   PubMed Web of Science ®Google Scholar
• Muller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert Opin Pharmacother 2006;7(13):1715-30
   PubMed Web of Science ®Google Scholar
• Metman LV, Del Dotto P, LePoole K, Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56(11):1383-6
   PubMed Web of Science ®Google Scholar
• Muller T. Dopaminergic substitution in Parkinson's disease. Expert Opin Pharmacother 2002;3(10):1393-403
   PubMedGoogle Scholar
• Muller T, Kuhn W, Schulte T, Przuntek H. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease. Neurosci Lett 2003;339(1):25-8
   PubMed Web of Science ®Google Scholar
• Perry EK, Kilford L, Lees AJ, Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol 2003;54(2):235-8
   PubMed Web of Science ®Google Scholar
• Rezak M. Current pharmacotherapeutic treatment options in Parkinson's disease. Dis Mon 2007;53(4):214-22
   PubMedGoogle Scholar
• Brooks DJ. Examining Braak's hypothesis by imaging Parkinson's disease. Mov Disord 2010;(25 Suppl 1):S83-8
   Google Scholar
• Moro E, Hamani C, Poon YY, Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain 2010;133(Pt 1):215-24
   PubMed Web of Science ®Google Scholar
• Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004;111(2):201-16
   PubMed Web of Science ®Google Scholar
• Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 2004;291(3):358-64
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287(13):1653-61
   PubMed Web of Science ®Google Scholar
• Whone AL, Watts RL, Stoessl AJ, Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003;54(1):93-101
   PubMed Web of Science ®Google Scholar
• Clarke CE. A ‘cure’ for Parkinson's disease: can neuroprotection be proven with current trial designs? Mov Disord 2004;19(5):491-8
   PubMed Web of Science ®Google Scholar
• Goetz CG, Leurgans S, Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. Mov Disord 2002;17(2):283-8
   PubMed Web of Science ®Google Scholar
• Jankovic J, McDermott M, Carter J, Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990;40(10):1529-34
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39(1):37-45
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Chen JJ. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007;27(12 Pt 2):174S-185S
   PubMed Web of Science ®Google Scholar
• Przuntek H, Conrad B, Dichgans J, SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa. Eur J Neurol 1999;6(2):141-50
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Olanow C, Rascol O. The ADAGIO Study: secondary and additional endpoints. Neurology 2009;72(Suppl 3):S42.008
   Google Scholar
• Olanow CW, Rascol O, Hauser R, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Shapira A, Albrecht S, Barone P, Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study. Parkinsonism Relat Disord 2009;15(Suppl 2):S81
   PubMed Web of Science ®Google Scholar
• Weiner WJ. There is no Parkinson disease. Arch Neurol 2008;65(6):705-8
   PubMed Web of Science ®Google Scholar
• Birkmayer W, Riederer P, Youdim BH. Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg 1979;81(3):158-64
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Martinez-Martin P, Brown RG, The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007;22(13):1901-11
   PubMed Web of Science ®Google Scholar
• Goetz CG, Laska E, Hicking C, Placebo influences on dyskinesia in Parkinson's disease. Mov Disord 2008;23(5):700-7
   PubMed Web of Science ®Google Scholar
• Goetz CG, Damier P, Hicking C, Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007;22(2):179-86
   PubMed Web of Science ®Google Scholar
• Gregoire L, Samadi P, Graham J, Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism Relat Disord 2009;15(6):445-52
   PubMed Web of Science ®Google Scholar
• Olanow CW, Damier P, Goetz CG, Multicenter, open-label, trial of sarizotan in Parkinson disease patients with levodopa-induced dyskinesias (the SPLENDID Study). Clin Neuropharmacol 2004;27(2):58-62
   PubMed Web of Science ®Google Scholar
• Binda C, Wang J, Pisani L, Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs. J Med Chem 2007;50(23):5848-52
   PubMed Web of Science ®Google Scholar
• Fariello RG. Safinamide. Neurotherapeutics 2007;4(1):110-16
   PubMed Web of Science ®Google Scholar
• Stocchi F, Arnold G, Onofrj M, Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004;63(4):746-8
   PubMed Web of Science ®Google Scholar
• Stocchi F, Vacca L, Grassini P, Symptom relief in Parkinson disease by safinamide: biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 2006;67(7 Suppl 2):S24-29
   PubMed Web of Science ®Google Scholar
• Bronzova J, Sampaio C, Hauser RA, Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord 2010;25(6):730-8
   Web of Science ®Google Scholar
• Hauser RA, Bronzova J, Sampaio C, Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. Eur Neurol 2009;62(1):40-8
   PubMed Web of Science ®Google Scholar
• Chat-Mendes C, Platt DM, Newman AH, Spealman RD. The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. Psychopharmacology (Berl) 2009;206(1):73-84
   PubMed Web of Science ®Google Scholar
• Brooks DJ, Papapetropoulos S, Vandenhende F, An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clin Neuropharmacol 2010;33(2):55-60
   PubMed Web of Science ®Google Scholar
• Jankovic J. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol 2008;63(3):267-9
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Greeley DR, Zweig RM, Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism Relat Disord 2010;16(1):16-20
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Guttman M, Tetrud JW, Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces ‘off’ time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 2008;63(3):295-302
   PubMed Web of Science ®Google Scholar
• Stacy M, Silver D, Mendis T, A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008;70(23):2233-40
   PubMed Web of Science ®Google Scholar
• Ouattara B, Gregoire L, Morissette M, Metabotropic glutamate receptor type 5 in levodopa-induced motor complications. Neurobiol Aging 2009;113(3):715-24
   Google Scholar
• Yamamoto N, Soghomonian JJ. Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by L-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats. Neuroscience 2009;163(4):1171-80
   PubMed Web of Science ®Google Scholar
• Johnston TH, Fox SH, McIldowie MJ, Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010;333(3):865-73
   PubMed Web of Science ®Google Scholar
• Buck K, Voehringer P, Ferger B. The alpha(2) adrenoceptor antagonist idazoxan alleviates L-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. J Neurochem 2010;112(2):444-52
   PubMed Web of Science ®Google Scholar
• Muller T, Renger K, Kuhn W. Levodopa associated homocysteine increase and sural axonal neurodegeneration. Arch Neurol 2004;61:657-60
   PubMed Web of Science ®Google Scholar
• Onofrj M, Bonanni L, Cossu G, Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism Relat Disord 2009;(15 Suppl 3):S233-6
   Google Scholar
• Block G, Liss C, Reines S, Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37(1):23-7
   PubMed Web of Science ®Google Scholar
• Hsu A, Verhagen L, Ellenbogen A, Comparison of IPX066, a novel extended-release oral carbidopa-levodopa formulation to immediate-release carbidopa-levodopa in patients with Parkinson's disease. Neurology 2010;74(Suppl 2):A350
   Google Scholar
• Abbas A, Roth BL. Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 2008;9(18):3251-9
   PubMed Web of Science ®Google Scholar
• Friedman J, Bernard R, Mills R, Multi-center, placebo-controlled, double-blind trial to examine the safety and efficacy of Pimvabserin in the treatment of psychosis in Parkinson's disease. Neurology 2010;74(Suppl 2):A299
   Google Scholar
• Weiner WJ. What do clinical trials tell us about treating patients. Parkinsonism Relat Disord 2009;15(Suppl 3):S34-37
   PubMed Web of Science ®Google Scholar
• Bjorklund T, Kordower JH. Gene therapy for Parkinson's disease. Mov Disord 2010;25(Suppl 1):S161-73
   PubMed Web of Science ®Google Scholar
• Feng LR, Maguire-Zeiss KA. Gene therapy in Parkinson's disease: rationale and current status. CNS Drugs 2010;24(3):177-92
   PubMed Web of Science ®Google Scholar
• Xu Q, Jiang X, Ke Y, Gene therapy in hemiparkinsonian rhesus monkeys: long-term survival and behavioral recovery by transplantation of autologous human tyrosine hydroxylase-expressing neural stem cells. Cytotherapy 2010;12(2):226-37
   PubMed Web of Science ®Google Scholar
• Lim ST, Airavaara M, Harvey BK. Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS. Pharmacol Res 2010;61(1):14-26
   PubMed Web of Science ®Google Scholar
• Manfredsson FP, Okun MS, Mandel RJ. Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson's disease. Curr Gene Ther 2009;9(5):375-88
   PubMed Web of Science ®Google Scholar
• Stover NP, Watts RL. Spheramine for treatment of Parkinson's disease. Neurotherapeutics 2008;5(2):252-9
   PubMed Web of Science ®Google Scholar
• Farag ES, Vinters HV, Bronstein J. Pathologic findings in retinal pigment epithelial cell implantation for Parkinson disease. Neurology 2009;73(14):1095-102
   PubMed Web of Science ®Google Scholar
• Muller T. Role of homocysteine in the treatment of Parkinson's disease. Expert Rev Neurother 2008;8(6):957-67
   PubMedGoogle Scholar
• Fahn S, Oakes D, Shoulson I, Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351(24):2498-508
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241-8
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463):947-54
   PubMed Web of Science ®Google Scholar
• Thomas A, Iacono D, Luciano AL, Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75(1):141-3
   PubMed Web of Science ®Google Scholar
• Verhagen ML, Del Dotto P, van den MP, Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease [see comments]. Neurology 1998;50(5):1323-6
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937-43
   PubMed Web of Science ®Google Scholar
• Hauser RA, Lew MF, Hurtig HI, Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 2009;24(4):564-73
   PubMed Web of Science ®Google Scholar
• Shults CW, Oakes D, Kieburtz K, Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59(10):1541-50
   PubMed Web of Science ®Google Scholar
• Storch A, Jost WH, Vieregge P, Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol 2007;64(7):938-44
   PubMed Web of Science ®Google Scholar
• Olanow CW, Schapira AH, LeWitt PA, TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5(12):1013-20
   PubMed Web of Science ®Google Scholar
• Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord 2002;8(4):271-6
   PubMed Web of Science ®Google Scholar
• Olanow CW, Hauser RA, Gauger L, The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38(5):771-7
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284(15):1931-8
   PubMed Web of Science ®Google Scholar
• Oertel WH, Wolters E, Sampaio C, Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006;21(3):343-53
   PubMed Web of Science ®Google Scholar